ITF Therapeutics
The Sr. Director, Integrated Performance Insights & Forecasting leads performance analytics, forecasting, and integrated insights for rare disease brands, leveraging specialty pharmacy, claims, EMR, CRM, and other data sources. The role serves as a strategic partner to senior leadership and cross‑functional teams, translating complex data into actionable recommendations to optimize commercial execution and forecast accuracy.
Headquarters
Concord, Massachusetts, United States
Company Size
1-10 employees
Founded
2024
ITF Therapeutics LLC is the United States affiliate of Italfarmaco S.p.A., founded in 2024 and based in Concord, MA. The company focuses on bringing therapeutic options to people living with rare diseases, most notably commercializing DUVYZAT (givinostat), an FDA‑approved HDAC inhibitor for Duchenne muscular dystrophy (DMD), in the U.S. market. ITF combines a flexible, entrepreneurial approach with the resources and legacy of its parent organization to deliver treatments, support programs, and educational resources for patients, clinicians, and researchers.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ITF Therapeutics.
54% above the average for this role
Senior Manager, Integrated Insights & Strategy
Pfizer
CRM Performance & Insights Manager
Wolverine Worldwide
Associate Director, Data Partnerships - Rare Disease
Novartis
Associate Director, Data Partnerships - Rare Disease
Novartis
AD, Data Partnerships - Rare Disease
lifelancer
Insights and Forecasting Director
AstraZeneca